ArticleCirculation. Heart failure2020
Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation.
Abstract readLetter
In one paragraph
Article in Circulation. Heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.Journal of the American Heart Association · 2021Trial
- Transpulmonary Proteome Gradients Identify Pathways Involved in Pulmonary Vascular Disease Due To Heart Failure.Circulation. Heart failure · 2025Observational
- Sacubitril/Valsartan Improves Hemodynamic Parameters of Pulmonary and Systemic Circulation in Patients Awaiting Heart Transplantation.Journal of clinical medicine · 2025Article
- Risk Factors for Adverse Outcomes in Connective Tissue Disease-Associated Pulmonary Hypertension.Reviews in cardiovascular medicine · 2025Review
- Who is the Candidate? The Heart Transplant Evaluation Process.Methodist DeBakey cardiovascular journal · 2025Review
- Pharmacologic Treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction: Are There More Arrows on Our Bow?Journal of clinical medicine · 2024Article
- Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats.Journal of aerosol medicine and pulmonary drug delivery · 2024Review
- Management of pulmonary hypertension associated with valvular heart disease with angiotensin-receptor neprilysin inhibitor.Pulmonary circulation · 2023Article
- Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial.American heart journal plus : cardiology research and practice · 2023Article
- The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure.Frontiers in cardiovascular medicine · 2023Review
- The history and mystery of sacubitril/valsartan: From clinical trial to the real world.Frontiers in cardiovascular medicine · 2023Review
- Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022Article
- Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension.Pulmonary circulation · 2022Review
- Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction.ESC heart failure · 2021Article
- Recent and Upcoming Drug Therapies for Pediatric Heart Failure.Frontiers in pediatrics · 2021Review
- Getting the "Right" Perspective on Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.Journal of the American Heart Association · 2020Article
- Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series.Journal of cardiovascular and thoracic research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Emily K ZernDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (E.K.Z., S.C., M.A.H., M.M.K.).
Susan ChengDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (E.K.Z., S.C., M.A.H., M.M.K.).
Aaron M WolfsonSarver Heart Center, University of Arizona, Tucson (A.M.W.).
Michele A HamiltonDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (E.K.Z., S.C., M.A.H., M.M.K.).
Michael R ZileDepartment of Cardiology, Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston (M.R.Z.).
Scott D SolomonCardiovascular Division, Brigham and Women's Hospital, Boston, MA (S.D.S.).
Michelle M KittlesonDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (E.K.Z., S.C., M.A.H., M.M.K.).
Funding
Cardiac microstructure and the immune-inflammatory response to SARS-CoV-2R01HL131532 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHENG, SUSAN, LI, DEBIAO · 2016 to 2025
$6.6MMediators of Systemic Inflammation and Heart Failure Risk in the CommunityR01HL143227 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHENG, SUSAN · 2019 to 2022
$3.3MInflammatory Mediators, Cardiovascular Health, and Longevity in WomenR01HL134168 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHENG, SUSAN · 2016 to 2019
$1.6MNHLBI NIH HHS R01 HL131532NHLBI NIH HHS R01 HL134168NHLBI NIH HHS R01 HL143227
Abstract
PubMed holds no abstract for this paper.
Indexed as
Heart TransplantationWaiting ListsAminobutyratesAngiotensin II Type 1 Receptor BlockersBiphenyl CompoundsDrug CombinationsHeart FailureHemodynamicsHumansHypertension, PulmonaryNeprilysinProtease InhibitorsRecovery of FunctionTetrazolesTime FactorsTreatment OutcomeAminobutyratesAngiotensin II Type 1 Receptor BlockersBiphenyl CompoundsDrug CombinationsNeprilysinProtease Inhibitorssacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanangiotensindiuresisejection fractionheart failurehypertension
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.